AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation to Telisotuzumab Vedotin for Previously Treated Non-Small Cell Lung Cancer Pharmaceutical Investing
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Passes Planned Interim Safety Analysis Life Science Investing
NEW SURVEY FROM BAUSCH + LOMB AND GLAUCOMA RESEARCH FOUNDATION REVEALS EMOTIONAL AND SOCIAL IMPACT OF HYPEREMIA ON GLAUCOMA PATIENTS Pharmaceutical Investing
Bristol Myers Squibb to Present at J.P. Morgan's 40th Annual Healthcare Conference Pharmaceutical Investing
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older Pharmaceutical Investing
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts Pharmaceutical Investing
KEYTRUDA® Plus LENVIMA® Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy Pharmaceutical Investing
